search
Back to results

Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients (NAVPRO)

Primary Purpose

Ventilator Associated Pneumonia

Status
Withdrawn
Phase
Phase 4
Locations
Colombia
Study Type
Interventional
Intervention
Sultamicillin
Sponsored by
Hospital Pablo Tobón Uribe
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Ventilator Associated Pneumonia focused on measuring Ventilator associated pneumonia, Coma, Brain Injuries, Intensive care units, antibiotic prophylaxis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All patients admitted to intensive care units,with score in the Glasgow Coma scale less than nine.
  • Requiring mechanical ventilation for more than 48 hours
  • Includes all patients with structural or metabolic coma

Exclusion Criteria:

  • Pregnant women
  • History of allergic reactions to ampicillin sulbactam
  • Patients admitted as potential organ donors
  • Patients with an indication of antibiotic therapy, or who have received more than 2 doses of any antibiotic previously.
  • Hospital stay for more than 48 hours before intubation.

Sites / Locations

  • Hospital Pablo Tobón Uribe

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Sultamicillin, Antibiotic Prophylaxis

Placebo

Arm Description

Sultamicillin, Antibiotic Prophylaxis

Physiologic Sodium Chloride Solution

Outcomes

Primary Outcome Measures

Impact of prophylaxis with ampicillin sulbactam versus placebo on the incidence of early ventilator-associated pneumonia
To determine the impact of prophylaxis with ampicillin sulbactam versus placebo on the incidence of early ventilator-associated pneumonia in patients with altered level of consciousness with a score on the Glasgow Coma Scale less than or equal to 8 and requiring mechanical ventilation for more than 48 hours

Secondary Outcome Measures

Effect of antibiotic prophylaxis versus placebo on the incidence of other infections
Compare the effect of antibiotic prophylaxis versus placebo on the incidence of later ventilator-associated pneumonia, as well as in other non-pulmonary infections (catheter sepsis, bacteremia, meningitis, urinary tract infection).

Full Information

First Posted
May 4, 2010
Last Updated
May 21, 2016
Sponsor
Hospital Pablo Tobón Uribe
search

1. Study Identification

Unique Protocol Identification Number
NCT01118403
Brief Title
Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients
Acronym
NAVPRO
Official Title
Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients: A Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2016
Overall Recruitment Status
Withdrawn
Why Stopped
He could not be started due to lack of funds
Study Start Date
March 2011 (undefined)
Primary Completion Date
March 2011 (Actual)
Study Completion Date
March 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospital Pablo Tobón Uribe

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study seeks to assess whether coma patients really benefit from the use of antibiotics as a prophylactic for reducing the incidence of early ventilator-associated pneumonia in this population group. For this we consider the use of ampicillin sulbactam antibiotic which has a low ability to induce resistance, efficacy and safety observed during the time that has been used, even in patients with neurosurgical pathology, and to be broadly available in our environment. Our hypothesis is that neurological patients in coma state, requiring mechanical ventilation, the application of antibiotic prophylaxis compared with placebo reduces the incidence of early ventilator-associated pneumonia.
Detailed Description
Ventilator-associated pneumonia (VAP) is one of the most common nosocomial infections occur in intensive care units, with frequencies ranging between 15% and 45%, which determine an attributable mortality of 25% to 27% Patients with compromised state of consciousness brought to mechanical ventilation, have a much higher reported incidence that patients without neurological involvement, reaches between 44 and 70%. These data have led to plan the implementation of strategies to reduce the incidence of early pneumonia in this population group, to thereby favorably influence the high rates of mortality, morbidity and costs that arise. Then we design this study to assess whether these patients really benefit from the use of antibiotics as a prophylactic, considering also the high impact that this would have given the high incidence of early ventilator-associated pneumonia in this population group.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ventilator Associated Pneumonia
Keywords
Ventilator associated pneumonia, Coma, Brain Injuries, Intensive care units, antibiotic prophylaxis

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sultamicillin, Antibiotic Prophylaxis
Arm Type
Experimental
Arm Description
Sultamicillin, Antibiotic Prophylaxis
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Physiologic Sodium Chloride Solution
Intervention Type
Drug
Intervention Name(s)
Sultamicillin
Other Intervention Name(s)
Sulbactam Ampicillin, Unasyn
Intervention Description
Ampoules per 1.5 grams, three grams intravenously every 6 hours for 4 doses diluted in physiologic Sodium Chloride Solution
Primary Outcome Measure Information:
Title
Impact of prophylaxis with ampicillin sulbactam versus placebo on the incidence of early ventilator-associated pneumonia
Description
To determine the impact of prophylaxis with ampicillin sulbactam versus placebo on the incidence of early ventilator-associated pneumonia in patients with altered level of consciousness with a score on the Glasgow Coma Scale less than or equal to 8 and requiring mechanical ventilation for more than 48 hours
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Effect of antibiotic prophylaxis versus placebo on the incidence of other infections
Description
Compare the effect of antibiotic prophylaxis versus placebo on the incidence of later ventilator-associated pneumonia, as well as in other non-pulmonary infections (catheter sepsis, bacteremia, meningitis, urinary tract infection).
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients admitted to intensive care units,with score in the Glasgow Coma scale less than nine. Requiring mechanical ventilation for more than 48 hours Includes all patients with structural or metabolic coma Exclusion Criteria: Pregnant women History of allergic reactions to ampicillin sulbactam Patients admitted as potential organ donors Patients with an indication of antibiotic therapy, or who have received more than 2 doses of any antibiotic previously. Hospital stay for more than 48 hours before intubation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carlos A Cadavid, MD
Organizational Affiliation
Hospital Pablo Tobón Uribe
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Pablo Tobón Uribe
City
Medellín
State/Province
Antioquia
ZIP/Postal Code
57
Country
Colombia

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients

We'll reach out to this number within 24 hrs